JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson to Neutral with an unchanged price target of $150.
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72.
The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however.
Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
TheFly.com, Inc.'s staff does NOT provide any individual investment advice or money management assistance. TheFly.com, Inc.'s employees are not brokers, dealers or registered investment advisors and do not attempt to influence the sale or purchase of securities. Nor does TheFly.com, Inc. respond to any email requests for guidance with regard to securities.
TheFly.com's news is intended for informational purposes only and does not claim to be actionable for investment decisions.
Comments
Log in or sign up to join the conversation.